Depressive symptoms, poor sleep quality, and systemic markers of inflammation (e.g., interleukin (IL)-6) are frequently associated. Interferon-alpha (IFN-a) therapy results in Major Depressive Disorder (MDD) in some people, offering the possibility to elucidate the relationship of MDD to sleep and inflammation during treatment. In particular, delineating the temporal relations among these factors could help inform their causal relationships. To this end, a cohort of 95 non-depressed hepatitis C patients was followed prospectively for four consecutive months during IFN-a therapy. We found that higher pre-treatment levels of circulating IL-6 predicted incidence of MDD (X 2 (1) = 7.7; p < 0.05). Time-lagged mixed-effect analyses supported uni-directional associations in which IL-6 predicted next month's PSQI scores (F(47, 11.6) = 78.4; p < 0.0005), and PSQI scores predicted next month's depressive Beck Depression Inventory-II (BDI) scores (F(16, 22.6) = 3.4; p < 0.005). In addition, on any given month of treatment, IL-6 levels predicted BDI symptoms the following month (F(16, 97.5) = 7.3; p < 0.0005), and conversely BDI predicted next month's IL-6 (F(14, 7.4) = 5.2; p < 0.05) -providing evidence for a positive feedback relationship between depressive symptoms and systemic inflammation. These data provide further evidence that high levels of inflammation and poor sleep quality may be risk factors for IFN-a induced depression. Furthermore, these findings highlight the complex temporal relationships that exist among sleep, depression, and inflammation, and support the need for further prospective investigations to elucidate the dynamics that underlie depression during IFN-a treatment.
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Introduction
Major Depressive Disorder (MDD) is associated with the onset and progression of several medical conditions (Eaton et al., 1996; Everson-Rose and Lewis, 2005; Frasure-Smith et al., 1993; Zautra et al., 1994) . One link between MDD and illness is inflammation, which plays an essential role in the pathogenesis of a number of chronic diseases, including cardiovascular disease, diabetes, and cancer (Antoni et al., 2006; Black, 2003; Papanicolaou et al., 1998; Pradhan et al., 2001; Pradhan and Ridker, 2002; Ridker et al., 2000) . Relatedly, elevations in systemic inflammation have been observed in patients with MDD (Howren et al., 2009; Raison et al., 2006; Zorrilla et al., 2001) , as evinced by increases in circulating levels of interleukin (IL)-6, when compared to non-depressives (Frommberger et al., 1997; Maes et al., 1995; Musselman et al., 2001b; Pike and Irwin, 2006; Sluzewska et al., 1996 ).
An emerging literature suggests that proinflammatory cytokines may contribute to the development of depressive symptoms including depressed mood, anhedonia, fatigue, and impaired sleep (Dantzer et al., 2008; Irwin and Miller, 2007; Raison et al., 2006) . IL-6 and its receptor are synthesized in the brain (Schobitz et al., 1994) , with high densities in the hippocampus and hypothalamus (Hopkins and Rothwell, 1995) . Healthy humans treated with an acute inflammatory stimulus (e.g., Salmonella abortis equi endotoxin or typhoid vaccination) exhibit significant increases in depressive symptoms, decreases in cognitive functioning, and alterations in sleep electrophysiology (Haack et al., 2001; Mullington et al., 2000; Reichenberg et al., 2001; Wright et al., 2005) . Furthermore, there is growing evidence that cytokine antagonists mitigate these behavioral changes in rodents and have been shown to reduce depressive symptoms among patients with inflammatory conditions (Cohen et al., 2006; Dantzer et al., 2008; Tyring et al., 2006) . Nevertheless, it is also plausible that the converse may be true. In other words, depression may lead to changes in inflammatory cytokine levels. For instance, there is laboratory evidence that people with depression display exaggerated stress-related increases in inflammatory responses (Miller et al., 2005 
